GNPX Projected Dividend Yield
Genprex Inc ( NASDAQ : GNPX )Genprex is a clinical stage gene therapy company focusing on the development of gene-based therapies. Co.'s oncology platform utilizes its non-viral ONCOPREX™ Nanoparticle Delivery System. Co.'s primary oncology drug candidate, REQORSA™ Immunogene Therapy, is being developed in combination with cancer drugs to treat Non-Small Cell Lung Cancer and Small Cell Lung Cancer. The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. In diabetes, Co. has licensed from the University of Pittsburgh of the Commonwealth System of Higher Education multiple technologies relating to the development of a gene therapy product for each of Type 1 and Type 2 diabetes. 20 YEAR PERFORMANCE RESULTS |
GNPX Dividend History Detail GNPX Dividend News GNPX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |